Blockade of chemokine signaling in patients with multiple sclerosis

Tools

Item Type:	Article
Title:	Blockade of chemokine signaling in patients with multiple sclerosis
Creators Name:	Zipp, F., Hartung, H.P., Hillert, J., Schimrigk, S., Trebst, C., Stangel, M., Infante-Duarte, C., Jakobs, P., Wolf, C., Sandbrink, R., Pohl, C. and Filippi, M.
Abstract:	We assessed the safety and efficacy of orally administered CC chemokine receptor 1 (CCR1) antagonist in 105 patients with relapsing/remitting MS (RRMS) in a 16-week, randomized, double-blind, placebo-controlled trial. The primary endpoint was the cumulative number of newly active lesions on serial MRI scans. Other MRI, immunologic, and clinical outcomes were also explored. No significant treatment difference was observed for any tested MRI variable. CCR1 does not contribute to initial leukocyte infiltration in RRMS.
Keywords:	Chemokines, Leukocyte Chemotaxis, Immunosuppressive Agents, Magnetic Resonance Imaging, Multiple Sclerosis, Phenylurea Compounds
Source:	Neurology
ISSN:	0028-3878
Publisher:	American Academy of Neurology
Volume:	67
Number:	10
Page Range:	1880-1883
Date:	28 November 2006
Official Publication:	https://doi.org/10.1212/01.wnl.0000244420.68037.86
PubMed:	View item in PubMed

Repository Staff Only: item control page